Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

J, Mazières; G, Zalcman; L, Crinò; P, Biondani; F, Barlesi; T, Filleron; AM, Dingemans; H, Léna; I, Monnet; SI, Rothschild; F, Cappuzzo; B, Besse; L, Thiberville; D, Rouvière; R, Dziadziuszko; EF, Smit; J, Wolf; C, Spirig; N, Pecuchet; F, Leenders; JM, Heuckmann; J, Diebold; JD, Milia; RK, Thomas; O, Gautschi

doi:10.1200/jco.2014.58.3302

Public

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Shared by NobleBlocks on Feb 9, 2015 • 12:00 AM UTC

Authors:

Mazières J

Zalcman G

Crinò L

Abstract

Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains.Patients and methods In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in centers that tested f...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!